Grifols S.A. American Depositary Shares (GRFS)

FairStock Score: 70/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I look for durable businesses that earn high returns on capital and carry little debt. Grifols is a plasma-derived medicine maker with 25,258 employees. That industry can have regulatory and scale barriers, but the returns shown do not prove a wide moat. As of the 2026-10-13 close at $7.17, FairStock’s P/E is 9.43 and P/B is 1.52. Its Graham Number is $11.81, leaving a 39.29% margin of safety. The FCF yield is 8.8% on $487.7M trailing free cash flow, and the dividend yield is 3.86%. Those are attractive if they persist. The weak spots are clear: ROE is 6.93%, ROCE is 4.23%, and debt-to-equity is 1.17. The Altman Z-Score is 0.62, a red flag for financial fragility, even though the Piotroski F-Score is 7/9. In the second quarter of fiscal 2026, revenue was $1.9B and net income was $155.0M, with an 8.27% margin. Revenue growth has been negative in the provided data, while profit growth has been positive, but I prefer consistent top-line growth. The PEG ratio is 0.29, suggesting the price is low relative to profit growth, but that growth may be volatile. FairStock gives it 70/100 and no Lynch category because only 0 years of filed results are available, needing 3. In short, this is a statistically cheap, cash-generative but leveraged business. I would want debt reduced and returns on capital improved before calling it a high-quality compounder.

In plain English: Grifols makes medicines from human plasma and related diagnostic tests. The business is profitable and generates cash, but it carries a lot of debt and earns low returns on the money invested in it. At $7.17 a share, the price looks cheap compared with its earnings and accounting value, though the risks mean it is not a clean bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer